According to Regeneron, the drug is a bispecific antibody that binds to B-cell maturation antigen (BCMA) on cancerous plasma cells and CD3 on T cells, directing the immune system to attack and destroy ...

Cancer-hunting antibodies coupled with a natural compound found in soil microbes proved a powerful combination against an aggressive type of blood cancer, according to a new study from scientists at ...

Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood ...

This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period.

Worldwide, at least seven people have been "cured" of HIV—or at least have had long-term sustained remission. This means that ...

A revolutionary new type of "Trojan horse" cancer therapy, now being deployed under the National Health Service in England, ...

ResearchAndMarkets projects the AI medical diagnostics market to surge to $46.59 billion by 2034, driven by a blistering 33.72% CAGR. Private equity firms believe 2025 could eclipse 2024 as the ...

As startups navigate the growing biotech sector in Wales, here are five biotech companies that are making waves in 2025.

Will the U.S. government adopt price controls on prescription drugs? If so, what would they look like? Seeking Alpha analysts ...

Antibody-drug conjugates (ADCs) represent a mechanistically defined class of targeted therapeutics that combine monoclonal antibodies with cytotoxic payloads to achieve selective delivery to ...

John Mascarenhas, MD, discusses the rationale, mechanism, and design of the phase 1 INCA33989-101 and -102 trials investigating a CAL-R–targeted antibody for patients with essential thrombocythemia.

Drug maker Shanghai Henlius traces its history to 1992, when four ambitious young entrepreneurs formed Fosun Group to seize ...